{"disease":{"id":"dysentery","name":"Dysentery","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"ampicillin","indication_name":"Dysentery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Amebic dysentery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazol","indication_name":"Amebic dysentery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05156528","title":"Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":21000,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06838195","title":"Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04865497","title":"Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1050,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03854929","title":"Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":364,"lead_sponsor_name":"Oxford University Clinical Research Unit, Vietnam","has_results":false},{"nct_id":"NCT03561181","title":"Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT02736968","title":"Auranofin for Giardia Protozoa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT03527173","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02445963","title":"Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"U.S. Army Medical Research and Development Command","has_results":true},{"nct_id":"NCT03089879","title":"A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}